You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

Astellas doses first patient in Phase 3 study of ASP2138

Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe

GSK's Jemperli wins FDA priority review for advanced rectal cancer

Anbogen Therapeutics enters collaborative research agreement with University of Tokyo for ABT-301 evaluation across multiple tumour types

Leads Biolabs NDA for Opamtistomig accepted by China's CDE

Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline

Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment

Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance

Annexin Pharmaceuticals receives proposed INN vanexin for ANXV

Pillar Biosciences, LC-SCRUM-Asia and LSI Medience collaborate for liquid biopsy screening in lung cancer

BioArctic and Mesenkia sign research collaboration for glioblastoma antibody project

Tolerance Bio licenses clinical-stage IL-7 therapy from NeoImmuneTech

Merck and Moderna report positive Phase 3 melanoma trial results

Scancell announces UK authorisation for Phase 3 melanoma trial

Harbour BioMed IND for HBM7004 approved by China's NMPA

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026